Zepbound™ (tirzepatide) Approved for Chronic Weight Management
The most effective medication ever seen for weight loss was approved by the FDA this morning.
Zepbound™ contains the same active ingredient as Mounjaro™ (tirzepatide). Much like Novo Nordisk markets semaglutide as Ozempic™ and Rybelsus™ for diabetes, and Wegovy™ for chronic weight management, Zepbound™ is identical to Mounjaro™, but is indicated for medical weight loss.
In clinical studies, patients treated with Zepbound lost 20-22% of their body weight at the higher doses, or an average of 50 pounds. This is even more weight loss than the 15-16% which was seen in the Wegovy studies for medical weight loss.
The medication is recommended to be used in addition to a properly structured eating plan along with proper physical activity.
Keep in mind that Zepbound is not available for purchase, yet – Elli Lilly has announced it will be available after Thanksgiving, 2023. If you are interested in this treatment, now is a great time to check with your insurance company to see if you have coverage for anti-obesity medications like Wegovy and Zepbound.
We will not initiate Zepbound with a voicemail or portal message – if you are interested in starting Zepbound, please schedule a visit with Dr. Lazarus, Heather or Jamie after Thanksgiving.
Read the FDA announcement about the approval of Zepbound for chronic weight management here.
I would like to start on zepbound.
I would like to start on zepbound. 25 pounds overweight.
Hi Rosemary – thanks for your comment. Assuming you live in Colorado, please give us a call at 303-750-9454 to learn about become a patient at Clinical Nutrition Center. If you live out of state, visit obesitymedicine.org, and use the find a provider feature located in the top menu bar on the left side. Search for ABOM certified physicians in your home town.